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Summary In the Medical Research Council's lVth trial in Myelomatosis the possible benefit of adding
vincristine to first line treatment with intermittent melphalan and prednisone has been assessed. This was
analysed in 530 patients who were randomly allocated to receive vincristine or not. Survival was not improved
by the addition of vincristine. A total of 268 patients reached plateau phase on first line therapy. Of these 226
patients were rerandomised either to continue receiving first line therapy for a further year or to cease
therapy. At the present time there is a slight but not significant survival advantage in the group which
received no further treatment on reaching plateau.
Several multiple-drug chemotherapy regimens for
the treatment of myelomatosis have incorporated
vincristine (Lee et al., 1974; Salmon 1975;
Alexanian et al., 1977; Case et al., 1977; Medical
Research Council's Working Party on Leukaemia
in Adults, 1980a; Cornwell et al., 1982; Alexanian
& Dreicer, 1984; Bonnet et al. 1984). The value of
this drug in multiple-drug combinations has in
general been assessed by comparison with
melphalan and prednisone or with other
combination regimens not containing vincristine.
On this basis the addition of vincristine has been
judged to be helpful. However, no report has
appeared in which vincristine has been added to
first line therapy as a single randomised variable.
The Cancer and Leukaemia Group B carried out a
randomised controlled trial of the use of vincristine
and prednisone after the first 22 weeks of induction
therapy in myelomatosis (Cornwell et al., 1982).
Initial treatment comprised either melphalan,
BCNU or CCNU. In this study, the late
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introduction of prednisone and vincristine failed to
increase response rates or to prolong survival. The
IVth MRC Myelomatosis Trial was designed to
assess the value of vincristine in first line treatment
of myelomatosis. It admitted 530 previously
untreated patients who were randomised to receive
either: courses of melphalan and prednisone alone
or courses of the same drugs plus vincristine.
Patients reaching plateau phase were randomised
either to stop first line treatment or to continue this
for a further year.
Patients and methods
This report is based on entry into the MRC IVth
Trial in Myelomatosis. A total of 530 patients were
entered from 1st March 1980 to 28th February
1982. This analysis is based on follow-up to 1st
February 1984, the median follow-up time being 23
months at which time 319 patients had died. Entry
criteria for the trial were as follows:
All patients had at least two of the following
three criteria:
(i) Bone marrow sections or smear showing the
presence ofplasma cell infiltration.
(ii) Skeletal X-rays showing definite osteolytic
lesions.
(iii) A paraprotein detectable in the serum or urine.
In addition all patients were below 75 years of age
and had not received previous cytotoxic therapy or
radiotherapy except to localised lesions.
First line treatment
Patients were allocated therapy by a central
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telephone randomisation service based in Oxford.
The two treatment options were intermittent
courses of:
(i) melphalan 1Omg daily for 7 days orally
prednisone 40mg daily for 7 days orally
(ii) melphalan 1Omg daily for 7 days orally
vincristine 1 mg i.v. on day 1 only
prednisone 40mg daily for 7 days orally
The interval between the first date of each course
was normally 4 weeks. To allow for variability of
absorption of oral melphalan and differing
sensitivity to the drug the following modifications
were made if haematological toxicity was
encountered. Courses were postponed in preference
to reducing drug dosage. However, in the face of
marked thrombocytopenia or neutropenia following
a full course of chemotherapy subsequent courses
were reduced to 5 or 6 days at the same dose. If the
interval between each of 3 consecutive courses had
to be extended to more than 6 weeks because of
haematological toxicity the treatment was changed
to cyclophosphamide 600mgm-2 i.v. every 21
days.
Second line treatment
Patients whose disease progressed while on first line
treatment were instead given doxorubicin
30mgm-2 and N,N-Bis(2-chloroethyl)-N-nitro-
sourea (BCNU) 30mgm-2 as a single i.v. injection
repeated every 4 weeks for 8 courses. Physicians
were free to adopt any alternative regimen they
wished if patients were unresponsive or had become
unresponsive to first and second line treatment.
Management ofpatients presenting in renalfailure
Patients whose blood urea exceeded 15mmol -1 or
whose serum creatinine was above 200mol1- I after
a 48 h period of hydration, were put on a high fluid
intake (31 day-) and were randomised either to
receive or not to receive sufficient alkali to render
their urine neutral. There were 80 patients in this
group and the results of this policy have been
reported elsewhere (MRC Working Party on
Leukaemia in Adults, 1984). These patients were
randomiused in the main chemotherapy trial and
have been included in the present analysis.
Definition ofstable plateau phase
Patients who reached plateau on first line treatment
before 1st October 1983 were randomised either to
stop cytotoxic therapy or to continue on the same
therapy for 1 further year. Plateau was defined as:
(i) constant paraprotein level for 6 months; (ii)
stable urinary free light chain excretion for 6
months; (iii) stable haematological and clinical
condition. A total of 226 patients were re-
randomised at this stage. A further 42 patients
reached plateau phase after 1st October 1983. These
patients stopped first line chemotherapy at that
stage. Serum paraprotein and urinary free light
chain output g 1 creatinine were assessed on all
patients at three monthly intervals in the
Department of Immunology, University of
Birmingham as described previously (Cooper et al.,
1984).
Results
Survival in relation to allocated Ist line treatment
The overall survival in the trial analysed by
allocated treatment is shown in Figure 1. There is
no significant difference between the groups (x2X=
0.02 P>0.5). The median duration of survival for
all patients was 26 months.
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Fiwe 1 Survival according to allocated treatment.
Melphalan and prednisone ( ) (261); melphalan,
prednisone and vincristine (..---) (269). Numbers
in parentheses indicate number of patients randomised
to each arm. X2=0.02, NS.
There were 78 patients admitted to the trial who
died within the first 100 days from randomisation.
Many of these deaths may have occurred too soon
for treatment to have been effective. Analysis of
survival of those patients surviving > 100 days from
entry also revealed no significant difference in
survival =20.50, P>0.5).
When stratified according to the prognostic
groups identified previously (Medical ResearchROLE OF VINCRISTINE IN MYELOMATOSIS 155
Table I Analysis of survival in the IVth Myelomatosis Trial based on treatment allocation and stratified by prognostic
index
Allpatients Patients surviving 100 days
Observedl Observed!
Prognostic Treatment No. No. expected No. No. expected
groups group in group ofdeaths deaths x2 P in group ofdeaths deaths x2 P
MP 55 19 0.80 51 16 0.74
Good 1.86 0.17 2.77 0.1
MVP 65 30 1.19 63 28 1.24
MP 147 98 1.06 128 79 1.06
Intermediate 0.55 0.5 0.54 0.5
MVP 154 94 0.95 135 75 0.94
MP 59 40 0.91 38 20 0.79
Poor 0.88 0.3 2.84 0.09
MVP 50 38 1.12 34 23 1.31
MP 261 157 0.98 217 115 0.95
Overall
(adjusted) 0.17 0.7 0.68 0.4
MVP 269 162 1.02 232 126 1.05
Table II Causes of death in IVth Myelomatosis Trial analysed by treatment allocation
Deaths infirst Deaths after
100 days 100 days
Total No. No. No. No.
Cause ofdeath no. on MP on MVP on MP on MVP
Progressive myelomatosis 151 9 8 57 77
Pyogenic infection when tumour load not
immediately life threatening 51 15 10 14 12
Mainly renal failure 21 5 6 2 8
Cerebrovascular accident 12 2 2 6 2
Myocardial infarction 13 4 1 7 1
Haemorrhage 3 0 1 2 0
Melphalan overdose 2 0 0 1 1
Acute myeloblastic leukaemia 3 0 0 2 1
Died unexpectedly at home cause not known 15 1 3 8 3
Other unrelated causes 22 3 3 8 8
No final details obtained 26 3 2 8 13
Totals 319 42 36 115 126
Council's Working Party on Leukaemia in Adults
[1980b]), none of the groups benefitted from the
addition of vincristine. Overall, after adjustment for
prognostic group, no significant difference between
treatments was observed (X2=0.17, P>0.5 after
adjustment for prognostic groups). (Table I).
Causes of death were analysed in relation to first
line treatment allocation (Table II). The slightly
poorer survival in patients receiving vincristine is
not attributable to an excess of deaths in that
group of patients dying from
uncontrolled myelomatosis.
causes other than
Effect on duration ofsurvival ofextendingfirst line
treatmentfor afurther year after patients had
reachedplateau
Patients whose disease did not progress during first
line treatment and who did not die from other
causes were treated until their serum paraprotein156 I.C.M. MAcLENNAN & J. CUSICK
and urinary free light chain output reached stable
levels. A total of 268 patients reached stable plateau
phase, as defined in the methods section. Of these
226 patients were re-randomised either to continue
first line treatment for a further year or to stop
treatment. In either case patients were followed up
regularly and restarted on treatment or changed to
second line treatment if disease progression
occurred. The survival after second randomisation
for patients in the stop and continue groups is
shown in Figure 2. There was a small trend toward
a better survival in the "stop" group but this was
not significant (X2 = 1.47, P =0.2). This result was
not affected by the treatment allocated at initial
presentation (X2 = 1.53, P=0.2 after adjustment for
initial therapy). The level of response to treatment
achieved in patients who were rerandomised at
plateau was assessed (Table III). Twenty-nine
percent of the patients reaching plateau achieved
complete serological remission. There is a trend to
better survival in patients achieving good responses
to chemotherapy. In each of the subgroups defined
by level of response the stop group patients fared
slightly better than those who were randomised to
continue therapy. However, follow-up of the stop:
continue randomisation is too short to draw final
conclusions.
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Fiwe 2 Survival from second randomisation ac-
cording to maintenance policy. Stop cytotoxic therapy
until signs of progression ( ) or continue cytotoxic
therapy for one further year (. ). Numbers in
parentheses indicate number of patients randomised to
each arm. x2 = 1.47; P=002
Table I Level ofserological response at plateau in patients randomised to stop or continue treatment
Second randomisation
STOP
CONTINUE
No response but stable
disease
7
>(571)
12
Partial response
without total loss of
urine light chain or
serwn paraprotein
36 (712)
39 (604)
Partial response with
total loss of urine light
chain or serwn
paraprotein
38 (769)
23 (766)
Complete response
with total loss ofboth
urine light chain and
serun paraprotein
29 (957)
33 (731)
Figures shown in the table are: numbers of patients in each group (60% actuarial survival in days post second
randomisation).
No response =Ur-ary light chain output g- creatinine <150% >50% of presentation values and serum
paraprotein < 125% >75% presentation values.
Partial response =Urinary light chain output g-' creatinine <50% of presentation values but .0.04gg-1 creatinine.
Serum paraprotein <75% starting values but still detectable.
Complete response =Urine light chain <0.04gg- creatinine and no detectable serum paraprotein.
In addition to the patients shown in the Table, 7 patients with non secretory myelomatosis were also rerandomised: 3 to
the stop group 4 to the continue group. Serum paraproteins were not assessed in 2 further patients at presentation.
The distribution of presentation serum paraprotein types and urinary light chain output in patients in this trial have been
reported previously (Cooper et al., 1984).ROLE OF VINCRISTINE IN MYELOMATOSIS 157
Discussion
An analysis of a number of 4 and 5-drug regimens
used by the South West Oncology Group
(Alexanian et al., 1977; Alexanian & Dreicer, 1984)
suggested that patients on regimens including vin-
cristine fared better than those treated with
protocols not including this agent. This viewpoint
was expressed in a BMJ editorial (1978) and the
results reported by Lee et al. (1974) Salmon (1975)
and later Case et al. (1977) were also cited as
confirmatory evidence. The Cancer and Leukaemia
group B on the other hand carried out a
randomised controlled trial in which vincristine and
prednisone were added late during first line therapy.
They failed to show that the addition of these
agents at 22 weeks had either increased the rate of
subsequent objective responses or prolonged
survival in patients treated with melphalan or nitro-
soureas . (Cornwell et al, 1982). Our trial was
designed to assess the value of the addition of
vincristine, at doses and intervals used by the South
West Oncology group to standard treatment with
intermittent melphalan and prednisone and no
benefit could be found.
Recently Barlogie et al. (1984) have reported
effective treatment of advanced myeloma refractory
to alkylating agents, with a regimen consisting of
high dose dexamethasone, and prolonged infusion
of vincristine and doxorubicin. It is difficult to
assess what role vincristine may have had in
achieving these responses.
There is no clear concensus in the literature
about the optimal duration of first line treatment in
myelomatosis. To some extent this will depend
upon the treatment used. As response rates vary
from patient to patient, it seems logical to relate
length of first line treatment to plateau phase rather
than to a fixed time from starting therapy. In the
third MRC trial patients were treated initially for 1
year only and were then rerandomised to receive
maintenance or no further chemotherapy (MRC
Working Party on Leukaemia in Adults, 1980a).
The duration of survival was slightly better in those
patients not receiving maintenance but this
difference is not significant. The South West
Oncology Group (1975) assessed the value of
continuing melphalan and prednisone for more than
1 year and concluded that this was of no major
value.
Other reports have appeared supporting the
policy of limiting the duration of first line treatment
(Alexanian et al. 1978; Paccagnella et al. 1983).
Arguments in favour of restricting the length of first
line treatment include: (i) an improved chance of
achieving second responses to chemotherapy when
disease subsequently progresses; (ii) reduction in
myelotoxicity, infection and secondary leukaemia
and (iii) improved quality of life in patients on
stable plateau phase who are not receiving chemo-
therapy. The present study has provided objective
evidence from a large randomised trial that first line
therapy with intermittent melphalan and prednisone
should not be continued after plateau phase has
been reached. It remains to be shown whether the
introduction of different cytotoxic agents at this
stage might be of benefit. However, cytokinetic
studies of patients' disease at plateau phase indicate
that residual disease may be inherently resistant to
further chemotherapy (Hokanson et al., 1977; Durie
et al., 1980).
The authors wish to thank the physicians throughout the
United Kingdom who entered patients to this study and
the members of the department of Immunology at the
University of Birmingham who carried out serial
paraproteins and urinary free light chain estimations on
all patients in the trial.
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